Intracellular synthesis of gold nanoparticles by Gluconacetobacter liquefaciens for delivery of peptide CopA3 and ginsenoside and anti-inflammatory effect on lipopolysaccharide-activated macrophages

被引:36
|
作者
Liu, Ying [1 ,2 ]
Perumalsamy, Haribalan [1 ,2 ]
Kang, Chang Ho [3 ,4 ]
Kim, Seung Hyun [1 ,2 ]
Hwang, Jae-Sam [5 ]
Koh, Sung-Cheol [6 ]
Yi, Tae-Hoo [1 ,2 ,3 ,4 ]
Kim, Yeon-Ju [1 ,2 ,3 ,4 ]
机构
[1] Kyung Hee Univ, Grad Sch Biotechnol, Gyeonggi Do, South Korea
[2] Kyung Hee Univ, Coll Life Sci, Gyeonggi Do, South Korea
[3] Gyeongsang Natl Univ, Div Appl Life Sci, Jinju, South Korea
[4] Gyeongsang Natl Univ, PMBBRC, Jinju, South Korea
[5] Natl Inst Agr Sci Rural Dev, Dept Agr Biol, Wonju, South Korea
[6] Korea Maritime & Ocean Univ, Dept Environm Engn, Busan, South Korea
基金
新加坡国家研究基金会;
关键词
Peptide CopA3; Compound K; gold nanoparticles; anti-inflammatory; NF-kappa B; NF-KAPPA-B; COMPOUND K; INFLAMMATORY RESPONSES; RAW264.7; CELLS; IN-VITRO; INHIBITION; PROLIFERATION; APOPTOSIS; PATHWAYS; EXTRACT;
D O I
10.1080/21691401.2020.1748639
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Probiotic Gluconacetobacter strains are intestinal microbes with beneficial effects on human health. Recently, researchers have used these strains to biosynthesize metal and non-metal nanoparticles for treating various chronic diseases. Despite their importance in nanotechnology, gold nanoparticles (AuNPs) biosynthesized by Gluconacetobacter species have not been clearly identified for treating inflammation and inflammation-associated diseases. While ginsenoside CK has strong pharmaceutical activity, it also has strong cytotoxicity and hydrophobicity which is hurdle to make formulation. Peptide-nanoparticle hybrids are gaining increasing attention for their potential biomedical applications, including human inflammatory diseases. Herein, we developed peptide CopA3 surface conjugated and ginsenoside compound K (CK) loaded gold nanoparticles (GNP-CK-CopA3), which intracellularly synthesised by the probiotic Gluconacetobacter liquefaciens kh-1, to target lipopolysaccharide (LPS)-activated RAW264.7 macrophages. The synthetic GNP-CK-CopA3 was characterised by various instrumental techniques. The results of our cellular uptake and MTT assays exhibited obvious drug intracellular delivery without significant cytotoxicity. In addition, pre-treatment with GNP-CK-CopA3 significantly ameliorated LPS-induced nitric oxide (NO) and reactive oxygen species (ROS) production and suppressed the mRNA and protein expression of pro-inflammatory cytokines in macrophages. Furthermore, GNP-CK-CopA3 efficiently inhibited the activation of the nuclear factor-kappa B (NF-kappa B) and mitogen-activating protein kinase (MAPK) signalling pathways. Taken together, our findings highlight the potential of using peptide-nanoparticle hybrids in the development of anti-inflammatory approaches and providing the experimental foundation for further application. [GRAPHICS] .
引用
收藏
页码:777 / 788
页数:12
相关论文
共 4 条
  • [1] Evaluation Anti-inflammatory Effect of Conjugated Gold Nanoparticles with Cortistatin Peptide as Drug Delivery to Asthmatic Lung Tissue
    Didar Mehrabi Nasab
    Alireza Taheri
    Seyyed Shamsadin Athari
    International Journal of Peptide Research and Therapeutics, 29
  • [2] Evaluation Anti-inflammatory Effect of Conjugated Gold Nanoparticles with Cortistatin Peptide as Drug Delivery to Asthmatic Lung Tissue
    Mehrabi Nasab, Didar
    Taheri, Alireza
    Athari, Seyyed Shamsadin
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2023, 29 (01)
  • [3] Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-α siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles
    Lokras, Abhijeet
    Thakur, Aneesh
    Wadhwa, Abishek
    Thanki, Kaushik
    Franzyk, Henrik
    Foged, Camilla
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2021, 8
  • [4] 2′,4-Dihydroxy-3′,4′,6′-trimethoxychalcone from Chromolaena odorata possesses anti-inflammatory effects via inhibition of NF-κB and p38 MAPK in lipopolysaccharide-activated RAW 264.7 macrophages
    Dhar, Rana
    Kimseng, Rungruedee
    Chokchaisiri, Ratchanaporn
    Hiransai, Poonsit
    Utaipan, Tanyarath
    Suksamrarn, Apichart
    Chunglok, Warangkana
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2018, 40 (01) : 43 - 51